<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00900445</url>
  </required_header>
  <id_info>
    <org_study_id>ACCL0631</org_study_id>
    <secondary_id>NCI-2011-02151</secondary_id>
    <secondary_id>CDR0000588173</secondary_id>
    <secondary_id>ACCL0631</secondary_id>
    <secondary_id>COG-ACCL0631</secondary_id>
    <secondary_id>ACCL0631</secondary_id>
    <secondary_id>U10CA095861</secondary_id>
    <nct_id>NCT00900445</nct_id>
  </id_info>
  <brief_title>Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Impact of Obesity on the Pharmacokinetics of Anticancer Therapy in Children With High Risk Acute Lymphoblastic Leukemia (ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <brief_summary>
    <textblock>
      This clinical trial is studying body mass index in younger patients receiving
      prednisone/prednisolone, vincristine, daunorubicin, and pegaspargase for high-risk acute
      lymphoblastic leukemia. Studying samples of blood from patients with cancer in the laboratory
      may help doctors learn more about the affect of body mass index on the way anticancer drugs
      work in the body. It may also help doctors predict how patients will respond to treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To compare the pharmacokinetics of prednisone/prednisolone, vincristine, and daunorubicin
      hydrochloride among obese, middle-weight, and underweight children aged 10 to less than 20
      years of age undergoing induction therapy for high-risk acute lymphoblastic leukemia.

      II. To examine the relationship between the above parameters and response status as defined
      by early response and induction failure

      OUTLINE: This is a multicenter study. Patients are stratified according to body mass index
      (BMI) (greater than or equal to 95th percentile [obese] vs 10th to 95th percentile [normal or
      at risk for overweight] vs less than or equal to 10th percentile [underweight]).

      Patients receive anticancer therapy as prescribed by their treating clinicians. Patients
      receive prednisone/prednisolone orally twice on either day 1 or day 8. Patients also receive
      daunorubicin hydrochloride IV over 30 minutes and vincristine IV once on the same day.

      Blood samples are obtained on either day 1 or day 8** of induction therapy for
      pharmacokinetic analysis of prednisone, daunorubicin hydrochloride, and vincristine activity
      levels.

      Blood samples are analyzed via high-performance liquid chromatography (HPLC),
      ultrafiltration, a Nessler reaction, ELISA, and liquid chromatography using reverse-phase
      chromatography, fluorescent detection, and solid-phase extraction.

      Demographic information, including ethnicity, is also collected. Weight and height is
      recorded at diagnosis and on the day pharmacokinetic assessment of vincristine, prednisone,
      and daunorubicin hydrochloride begins.

      NOTE: **Patients who are being sampled on day 8 of induction therapy and who have received
      intravenous corticosteroid therapy in the first week of induction must have received at least
      six oral prednisone/prednisolone doses prior to the morning prednisone/prednisolone dose on
      day 8.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date type="Actual">March 24, 2008</start_date>
  <primary_completion_date type="Actual">August 17, 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of prednisone/prednisolone</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 4, 6 to 8, 10 and 12 hours</time_frame>
    <description>Two multiple comparisons (normal weight versus obese and normal weight versus underweight groups) will be conducted with a priori planned contrasts using the Bonferroni adjustment method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of daunorubicin hydrochloride</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 2, 4, 8, 12, 24 to 36 hours, and 48 to 72 hours</time_frame>
    <description>Two multiple comparisons (normal weight versus obese and normal weight versus underweight groups) will be conducted with a priori planned contrasts using the Bonferroni adjustment method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of vincristine sulfate</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 4, 8, 24 to 36 hours, and 48 to 72 hours</time_frame>
    <description>Two multiple comparisons (normal weight versus obese and normal weight versus underweight groups) will be conducted with a priori planned contrasts using the Bonferroni adjustment method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RER and SER status</measure>
    <time_frame>Up to 1.5 years</time_frame>
    <description>To examine the relationship between pharmacokinetic parameters and RER versus SER status, univariate and multiple logistic regressions will be performed.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Untreated Childhood Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Basic science (pharmacokinetics)</arm_group_label>
    <description>Patients receive anticancer therapy as prescribed by their treating clinicians. Patients receive prednisone/prednisolone orally twice on either day 1 or day 8. Patients also receive daunorubicin hydrochloride IV over 30 minutes and vincristine IV once on the same day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Basic science (pharmacokinetics)</arm_group_label>
    <other_name>Cerubidin</other_name>
    <other_name>Cerubidine</other_name>
    <other_name>Cloridrato de Daunorubicina</other_name>
    <other_name>Daunoblastin</other_name>
    <other_name>Daunoblastina</other_name>
    <other_name>Daunoblastine</other_name>
    <other_name>Daunomycin Hydrochloride</other_name>
    <other_name>Daunomycin, hydrochloride</other_name>
    <other_name>Daunorubicin.HCl</other_name>
    <other_name>Daunorubicini Hydrochloridum</other_name>
    <other_name>FI-6339</other_name>
    <other_name>Ondena</other_name>
    <other_name>RP-13057</other_name>
    <other_name>Rubidomycin Hydrochloride</other_name>
    <other_name>Rubilem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Basic science (pharmacokinetics)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Basic science (pharmacokinetics)</arm_group_label>
    <other_name>(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione</other_name>
    <other_name>.delta.1-Hydrocortisone</other_name>
    <other_name>Adnisolone</other_name>
    <other_name>Aprednislon</other_name>
    <other_name>Capsoid</other_name>
    <other_name>Cortalone</other_name>
    <other_name>Cortisolone</other_name>
    <other_name>Dacortin H</other_name>
    <other_name>Decaprednil</other_name>
    <other_name>Decortin H</other_name>
    <other_name>Delta(1)Hydrocortisone</other_name>
    <other_name>Delta- Cortef</other_name>
    <other_name>Delta-Cortef</other_name>
    <other_name>Delta-Diona</other_name>
    <other_name>Delta-F</other_name>
    <other_name>Delta-Phoricol</other_name>
    <other_name>Delta1-dehydro-hydrocortisone</other_name>
    <other_name>Deltacortril</other_name>
    <other_name>Deltahydrocortisone</other_name>
    <other_name>Deltasolone</other_name>
    <other_name>Deltidrosol</other_name>
    <other_name>Dhasolone</other_name>
    <other_name>Di-Adreson-F</other_name>
    <other_name>Dontisolon D</other_name>
    <other_name>Estilsona</other_name>
    <other_name>Fisopred</other_name>
    <other_name>Frisolona</other_name>
    <other_name>Gupisone</other_name>
    <other_name>Hostacortin H</other_name>
    <other_name>Hydeltra</other_name>
    <other_name>Hydeltrasol</other_name>
    <other_name>Klismacort</other_name>
    <other_name>Kuhlprednon</other_name>
    <other_name>Lenisolone</other_name>
    <other_name>Lepi-Cortinolo</other_name>
    <other_name>Linola-H N</other_name>
    <other_name>Linola-H-Fett N</other_name>
    <other_name>Longiprednil</other_name>
    <other_name>Metacortandralone</other_name>
    <other_name>Meti Derm</other_name>
    <other_name>Meticortelone</other_name>
    <other_name>Opredsone</other_name>
    <other_name>Panafcortelone</other_name>
    <other_name>Precortisyl</other_name>
    <other_name>Pred-Clysma</other_name>
    <other_name>Predeltilone</other_name>
    <other_name>Predni-Coelin</other_name>
    <other_name>Predni-Helvacort</other_name>
    <other_name>Prednicortelone</other_name>
    <other_name>Prednisolonum</other_name>
    <other_name>Prelone</other_name>
    <other_name>Prenilone</other_name>
    <other_name>Sterane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Basic science (pharmacokinetics)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Basic science (pharmacokinetics)</arm_group_label>
    <other_name>Kyocristine</other_name>
    <other_name>Leurocristine sulfate</other_name>
    <other_name>Leurocristine, sulfate</other_name>
    <other_name>Oncovin</other_name>
    <other_name>Vincasar</other_name>
    <other_name>Vincosid</other_name>
    <other_name>Vincrex</other_name>
    <other_name>Vincristine, sulfate</other_name>
  </intervention>
  <eligibility>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be newly diagnosed with acute lymphoblastic leukemia and the intended
             induction treatment must contain prednisone/prednisolone, vincristine and daunorubicin
             in the doses and schedule as per the current COG AALL0232 protocol; prior registration
             onto a COG protocol is not required

          -  Patients must be able to take either prednisone/prednisolone reliably by mouth on day
             1 or 8 of induction (depending on sampling schedule chosen); patients who are being
             sampled on Induction day 8 and who have received intravenous corticosteroid therapy in
             the first week of induction must have received a minimum of six oral
             prednisone/prednisolone doses prior to the morning prednisone/prednisolone dose on
             induction day 8

        Exclusion Criteria:

          -  Serum transaminase concentrations &gt;= 5 X ULN for age

          -  Total serum bilirubin (conjugated + unconjugated) &gt;= 1.5 mg/dl (&gt;= 26 micromol/L)

          -  Serum creatinine &gt; 1.5 X ULN for age

          -  With the exception of prednisone/prednisolone, receipt of medications or food known or
             with the potential to alter the pharmacokinetics of the drugs under study within 14
             days of diagnosis and throughout the period of pharmacokinetic sampling; such agents
             include but are not limited to: grapefruit, tangelos or the juice of these fruits; St.
             Johns wort; anticonvulsants: carbamazepine, oxcarbazepine, phenytoin, phenobarbital,
             primidone; azole antifungal agents: ketoconazole, fluconazole, itraconazole,
             voriconazole; macrolide antibiotics: erythromycin, clarithromycin; isoniazid;
             rifampin; verapamil; and diltiazem

          -  Presence of known malabsorption syndrome

          -  Females with known pregnancy (pregnancy test must be negative to be eligible)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian Pollack</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Childrens Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
  </removed_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>August 3, 2018</last_update_submitted>
  <last_update_submitted_qc>August 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone hemisuccinate</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

